You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 611 Health status and utilization of health care programs of long-term survivors: survivorship clinic for long-term survivors with gynecological cancer

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
10. Quality of life after treatment
611 Health status and utilization of health care programs of long-term survivors: survivorship clinic for long-term survivors with gynecological cancer
  1. Hannah Woopen1,
  2. Stephanie Roll2,
  3. Jolijn Boer3,
  4. Petra Hühnchen4,
  5. Kirsten Wittke5,
  6. Adak Pirmorady6,
  7. Nicole Balint1,
  8. Frank Edelmann7,
  9. Knut Mai8,
  10. Bernd Wolfarth9,
  11. Fabian Meinert10,
  12. Cindy Stoklossa11,
  13. Thomas Reinhold2,
  14. Stefan Kommoss12,
  15. Suzana Mittelstadt12,
  16. Clemens Liebrich13,
  17. Barbara Schmalfeldt14,
  18. Tamara Boxler15,
  19. Pauline Wimberger16 and
  20. Jalid Sehouli1
  1. 1Department of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité—Universitätsmedizin Berlin, Berlin, Germany
  2. 2Institute of Social Medicine, Epidemiology and Health Economics of the Charité – Universitätsmedizin Berlin, Berlin, Germany
  3. 3North-Eastern German Society for Gynecological Oncology (NOGGO e.V.), Berlin, Germany
  4. 4Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin; Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Berlin, Germany
  5. 5Charité Fatigue Center, Charité – Universitätsmedizin Berlin, Berlin, Germany
  6. 6Department of Psychosomatic Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
  7. 7Department of Cardiology, Angiology and Intensive Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
  8. 8Department of Endocrinology and Metabolic Diseases (including Lipid Metabolism), Charité – Universitätsmedizin Berlin, Berlin, Germany
  9. 9Charité Sports Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany
  10. 10Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany
  11. 11Social services, Charité – Universitätsmedizin Berlin, Berlin, Germany
  12. 12Department of Women’s Health, University Hospital Tübingen, Tübingen, Germany
  13. 13Gynecological Cancer Center, Klinikum Wolfsburg – Gynecological Clinic, Wolfsburg, Germany
  14. 14Clinic and Polyclinic for Gynecology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
  15. 15Gynecological Cancer Center, Klinikum Fürth, Fürth, Germany
  16. 16Clinic and Polyclinic for Gynecology and Obstetrics, Universitätsklinikum Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany

Abstract

Introduction/Background Aim of the study is to establish a survivorship clinic for long-term survivors (LTS) with gynaecological cancer as a new form of care to improve quality of life. This preliminary analysis aims to evaluate their health status to gain further insight into LTS’ needs.

Methodology Non-randomized, controlled, multi-center, open intervention study with two parallel groups (n=180 per group). The intervention group takes part in the holistic survivorship clinic at Charité – Universitätsmedizin Berlin; the control group (recruited by the North-East German Society for Gynecological Oncology) receives routine follow-up care. Main inclusion criterion: gynaecological cancer at least five years ago. Primary endpoint is health-specific quality of life (SF-36) after 12 months; secondary endpoints include frequency and severity of long-term side effects.

Results A total of 373 LTS could be recruited: ovarian (n=249; 67%), cervical (n=83; 22%), endometrial cancer (n=41; 11%). Last patient-out will be 06/2024. Main comorbidities were hypertension (35%), arthrosis (33%) and hypothyroidism (24%). Comedications were documented in 80% of cases. Prior to recruitment, one-third of patients (35%) had been hospitalized within the preceding year, and 24% visited the emergency department. LTS had a median number of 12 physician contacts within one year (range: 1–160 consultations). Most frequent long-term side effects in the intervention group (n=192) were lymphedema (53%), vaginal dryness (50%), gastrointestinal symptoms (45%), psycho-oncological need (43%), memory problems (43%), polyneuropathy (42%) and sleeping disorders (42%). Altogether, 90 received optional specialized survivorship care from neurology (recommendations: n=147), 86 from mental health (recommendations: n=153), 52 from the fatigue centre (recommendations: n=108), and 43 from sexual medicine.

Conclusion LTS still experience a wide range of (tumor-/therapy-related) symptoms. Specialized survivorship care may help to coordinate health care for LTS with the aim of promoting physical and mental health in order to improve quality of life.

Disclosures Kommoss S:

Receipt of grants/research supports: GSK

Receipt of honoraria or consultation fees: GSK, Eisai, Astra Zeneca, MSD

Liebrich C:

Receipt of honoraria or consultation fees: Roche, Tesaro, GSK, MSK, NCO - New Concept Oncology

Schmalfeldt B:

Receipt of grants/research supports: Astra Zeneca, DaiichiSankyo, Roche, GSK, MSD, Eisai, MedConcept

Receipt of honoraria or consultation fees: Astra Zeneca, DaiichiSankyo, Roche, GSK, MSD, Eisai, MedConcept

Wimberger P:

Receipt of grants/research supports: Amgen, GSK, Clovis, AstraZeneca, MSD, Novartis, Pfizer, Lilly, Roche, Pierre Fabre

Receipt of honoraria or consultation fees: AstraZeneca, MSD, Eisai, Novartis, Roche, Amgen, Clovis, Pfizer, Gilliad, Lilly

Sehouli J:

Receipt of grants/research supports: AstraZeneca, Clovis Oncology, Merck, Bayer, PharmaMar, Pfizer, Tesaro, MSD Oncology, Roche

Receipt of honoraria or consultation fees: AstraZeneca, Clovis Oncology, PharmaMar, Merck, Pfizer, Tesaro, MSD Oncology, Lilly, Novocure, J&J, Roche, Ingress Health, Riemser, Sobi, GSK, Novartis, Eisai, Olympus Medical Systems, Pfizer, Teva, Bayer

https://doi.org/10.1136/ijgc-2024-ESGO.940

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.